Related Experiment Video
Updated: Jun 25, 2026
04:34
Mouse Body Temperature Measurement Using Infrared Thermometer During Passive Systemic Anaphylaxis and Food Allergy Evaluation
Published on: September 14, 2018
25.7K
The first successful desensitization protocol in exenatide allergy: a case report
Osman Ozan Yeğit1, Göktuğ Sarıbeyliler2, Pelin Karadağ3
1Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Topkapı, Turgut Özal Millet Street, Fatih, 34093, Istanbul, Turkey. drosmanozan@gmail.com.
Summary
This study demonstrates the first successful exenatide desensitization protocol for patients with immediate hypersensitivity reactions. This approach is crucial for obese diabetic patients requiring glucagon-like peptide-1 (GLP-1) receptor agonists when alternatives are unavailable.
Area of Science:
- Endocrinology
- Allergy and Immunology
- Pharmacology
Background:
- Glucagon-like peptide-1 (GLP-1) receptor agonists are vital for managing obese patients with type 2 diabetes.
- Immediate allergic reactions to GLP-1 receptor agonists are rare but can necessitate alternative treatments.
- Exenatide is the sole GLP-1 receptor agonist covered by insurance in Turkey, making desensitization a critical option.
Purpose of the Study:
- To report the first successful drug desensitization protocol for exenatide in patients experiencing immediate hypersensitivity reactions.
- To evaluate the safety and efficacy of exenatide desensitization in obese diabetic patients.
Main Methods:
- Two obese diabetic patients with immediate hypersensitivity to exenatide underwent a 7-step, 3-hour desensitization protocol.
- The protocol aimed to gradually reach the full daily dosage of exenatide.
- Patients were monitored for any adverse reactions during and after the desensitization process.
Main Results:
- Both patients successfully tolerated the exenatide desensitization protocol without any immediate complaints or complications.
- Following desensitization, patients safely continued exenatide treatment for three months.
- The protocol effectively managed both local injection site reactions and systemic hypersensitivity.
Conclusions:
- This study presents the first successful desensitization protocol for exenatide in cases of immediate hypersensitivity.
- Drug desensitization is a vital therapeutic option for patients with hypersensitivity reactions when alternative treatments are not feasible.
- The findings underscore the importance of desensitization protocols in managing type 2 diabetes patients on GLP-1 receptor agonists.
Related Concept Videos
02:06Allergic Reactions
Overview
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:30Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...